Medication info

Glitinaduo Tablet 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Light pink, oblong, biconvex film-coated tablet
Packaging
PTP - 60 tablets/PTP [10 tablets/PTP X 6]
Approval status
Expired

MFDS item code 201906454 · Approved 2019.09.16

This product's status changed to Expired on 2024.09.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined for each patient based on the current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may result in a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients in Whom This Medicine Must Not Be Administered).

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to assist blood sugar control in adults with type 2 diabetes. It is administered to patients who have not been previously treated for diabetes or have difficulty controlling blood sugar with monotherapy. It is also used when sufficient blood sugar control has not been achieved with metformin monotherapy or a combination of linagliptin and metformin. In cases where blood sugar control is difficult with the maximum dose of metformin in combination with sulfonylureas, insulin, or empagliflozin, this medication can be added to enhance therapeutic effect. Thus, this medication is used at various treatment stages to complement existing therapies and improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined for each patient based on the current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may result in a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients in Whom This Medicine Must Not Be Administered).

Precautions

This medication may cause a rare but serious side effect known as lactic acidosis, so it should not be used by patients with impaired kidney function or liver dysfunction. It should not be administered to patients who are allergic to the active ingredients or have certain heart and kidney conditions such as type 1 diabetes, diabetic ketoacidosis, or acute myocardial infarction. Due to the risk of hypoglycemia, blood sugar levels should be closely monitored and dosages adjusted when used in conjunction with other hypoglycemic agents such as insulin or sulfonylureas. Elderly patients with decreased kidney function or those taking medications that affect kidney function should undergo regular kidney function tests, and this medication should be temporarily discontinued in situations where kidney function may rapidly decline. Skin conditions such as acute pancreatitis or bullous pemphigoid may occur, so if persistent, severe abdominal pain or skin rash develops during treatment, consult a physician immediately. It is advisable to avoid using this medication in pregnant women or nursing mothers, and if planning a pregnancy, alternative treatment options should be discussed with a physician. Safety and efficacy in children and adolescents have not been established, thus usage is not recommended for children under 10 years of age. Alcohol consumption should be avoided during treatment, as the risk of lactic acidosis may increase, especially in cases of acute alcohol intoxication. If administration of radiologic iodinated contrast agents is required, this medication should be discontinued for a certain period before and after the examination, and kidney function should be reassessed. In cases of overdose, the risk of lactic acidosis is increased, thus immediate hospital treatment is necessary, which may include blood dialysis. Store this medication in a place out of reach of children, avoid moisture, and do not transfer to another container.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, vitamin B12 deficiency and reduction, hypoglycemia, taste disorders, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe and disability-associated arthralgia, rhabdomyolysis, increased lipase, increased amylase, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuritis, sepsis, pneumonia, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuritis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, dry eye, cataract, ocular discomfort, allergic conjunctivitis, polyuria, hypotension, flushing, hepatic steatosis, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, hearing loss, erectile dysfunction, goiter, kidney transplant failure, anemia, dizziness, sensory loss, chest discomfort, asthenia, epistaxis, oropharyngeal pain, voice disorders, nasal bleeding, benign prostatic hyperplasia, pruritus, insomnia, depression, hypertension, benign, malignant, and unspecified neoplasms (including cysts and polyps), confusion state, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, thus it should be stored in a sealed container. It is important to maintain storage temperature between 1 degree and 30 degrees Celsius. This helps ensure the medication's effectiveness and maintain quality.

Appearance and packaging

Appearance

Light pink, oblong, biconvex film-coated tablet

Package unit

PTP - 60 tablets/PTP [10 tablets/PTP X 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.